Clinical Trials

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04840602 2026-04-13

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

92 enrolled

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05272384 2026-04-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

32 enrolled

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05675410 2026-04-13

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

21 enrolled

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07069699 2026-04-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

50 enrolled

Burkitt Lymphoma

NCT06738368 2026-04-08

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05976763 2026-04-07

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 3 Recruiting

421 enrolled

Lymphoma, Mantle-Cell

NCT06675123 2026-04-07

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

10 enrolled

Lymphoma, Mantle-Cell

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Phase 3 Recruiting

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06863402 2026-03-24

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06918431 2026-03-17

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

53 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06442475 2026-03-13

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

20 enrolled

Lymphoma, Follicular

NCT06572618 2026-03-13

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT06784726 2026-03-13

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Lymphoma, Large B-Cell, Diffuse

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05801913 2026-03-05

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

15 enrolled

Lymphoma, B-Cell

NCT04195633 2026-02-27

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasm

60 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT06536049 2026-02-19

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Phase EARLY_PHASE1 Recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05800405 2026-02-04

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

9 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

396 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Lymphoma, Mantle-Cell

NCT05371132 2026-01-28

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

10 enrolled

Lymphoma, Neoplasm Metastasis

NCT06834373 2026-01-28

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

41 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07098364 2026-01-14

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

33 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06054776 2026-01-05

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

40 enrolled

Lymphoma, Mantle-Cell

NCT06522932 2025-12-29

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

32 enrolled

Lymphoma, Non-Hodgkin

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

35 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06447987 2025-12-17

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

24 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06948786 2025-11-26

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

22 enrolled

Lymphoma, Follicular

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

37 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04941716 2025-11-19

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

20 enrolled

Phase EARLY_PHASE1 Recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06735690 2025-11-12

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

15 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05011045 2025-11-10

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Recruiting

100 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06195891 2025-11-10

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

LymphoidMyeloidOther hematologic neoplasm

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

227 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies